drugset
drugset / Trial / NCT06081920

A Study of IBI363 in Subjects With Advanced Melanoma

NCT06081920 ↗

Phase 2 Recruiting 150 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients

Timeline

Start
2023-10-19
Primary completion
2025-06-06
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI363 Protein / enzyme biologic — —

Indications

melanoma